

**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Original) A blister form medicament pack comprising
  - (a) a base sheet in which blisters are formed to define pockets therein for the containment of inhalable medicament;
  - (b) a lid sheet which is sealable to the base sheet except in the region of the blisters and mechanically peelable from the base sheet to enable release of said inhalable medicament,

wherein said base sheet and/or said lid sheet have a laminate structure comprising (a) a first layer of aluminium foil; and (b) a second layer of polymeric material of thickness from 10 to 60 micron, said polymeric material having a water vapour permeability of less than 0.6 g /(100 inches<sup>2</sup>) (24 hours) (mil) at 25°C.

2. (Original) A blister form medicament pack according to claim 1, wherein the polymeric material is selected from the group consisting of polypropylene; polyethylene; polyvinylidene chloride (PVDC); polychlorotrifluoroethylene (PCTFE); cyclic olefin copolymer (COC); and cyclic olefin polymer (COP).

3. (Original) A blister form medicament pack according to claim 2, wherein the polymeric material is polypropylene having a form selected from the group consisting of oriented or cast form.

4. (Original) A blister form medicament pack according to claim 2, wherein the polymeric material is polyethylene having a form selected from the group consisting of high, low or intermediate density form.

5. (Previously Presented) A blister form medicament pack according to claim 1, in the form of an elongate peelable blister strip having multiple distinct blister portions provided along its length.

6. (Previously Presented) A blister form medicament pack according to claim 1, wherein the polymeric material of the second layer has a water vapour permeability of less than 0.3 g / (100 inches<sup>2</sup>) (24 hours) (mil) at 25°C.

7. (Previously Presented) A blister form medicament pack according to claim 1, wherein the thickness of the second layer is from 20 to 30 micron.

8. (Previously Presented) A blister form medicament pack according to claim 1, wherein the second layer is an inner layer of the pack.

9. (Previously Presented) A blister form medicament pack according to claim 1, wherein the lid sheet comprises at least the following successive layers: (a) paper; bonded to (b) plastic film; bonded to (c) aluminium foil.

10. (Original) A blister form medicament pack according to claim 9, wherein the aluminium foil is further provided with a layer of heat seal lacquer.

11. (Previously Presented) A blister form medicament pack according to claim 9, wherein said plastic film layer comprises a material selected from the group consisting of polyester, polyamide, polypropylene and PVC.

12. (Original) A blister form medicament pack according to claim 11, wherein the plastic film is an oriented plastic film comprising a material selected

from the group consisting of oriented polyamide (OPA), oriented polyester (OPET), and oriented polypropylene (OPP).

13. (Previously Presented) A blister form medicament pack according to claim 11, wherein the plastic layer has a thickness of from 5 to 40 µm.

14. (Previously Presented) A blister form medicament pack according to claim 9, wherein the aluminium layer has a thickness of from 15 to 60 µm.

15. (Previously Presented) A blister form medicament pack according to claim 1, wherein the base sheet comprises at least the following successive layers: (a) oriented polyamide (OPA); adhesively bonded to (b) aluminium foil; adhesively bonded to (c) a layer of thickness from 10 to 60 micron comprising the polymeric material having a water vapour permeability of less than 0.6 g /(100 inches<sup>2</sup>) (24 hours) (mil) at 25°C.

16. (Original) A blister form medicament pack according to claim 15, wherein the polymeric material comprises oriented polypropylene (OPP) and the thickness of the polymeric layer is from 20 to 30 micron.

17. (Original) A blister form medicament pack according to claim 15, wherein the polymeric material comprises cast polypropylene and the thickness of the polymeric layer is from 20 to 30 micron.

18. (Original) A blister form medicament pack according to claim 15, wherein the polymeric material comprises high density polyethylene (HDPE) and the thickness of the polymeric layer is from 35 to 45 micron.

19. (Original) A blister form medicament pack according to claim 15, wherein the polymeric material comprises low density polyethylene (LDPE) and the thickness of the polymeric layer is from 20 to 30 micron.

20. (Original) A blister form medicament pack according to claim 15, wherein the polymeric material comprises polyvinylidene chloride (PVDC) and the thickness of the polymeric layer is from 20 to 30 micron.

21. (Original) A blister form medicament pack according to claim 15, wherein the polymeric material comprises polychlorotrifluoroethylene (PCTFE) and the thickness of the polymeric layer is 20 to 45 micron.

22. (Original) A blister form medicament pack according to claim 15, wherein the polymeric material comprises cyclic olefin copolymer (COC) and the thickness of the polymeric layer is from 20 to 30 micron.

23. (Currently Amended) A blister form medicament pack according to any of claim 1, wherein one or more of said blisters of the pack contain inhalable medicament in dry powder form.

24. (Original) A blister form medicament pack according to claim 23, wherein said inhalable medicament comprises one or more medicament actives selected from the group consisting of anti-inflammatory agents, anticholinergic agents, other  $\beta_2$ -adrenoreceptor agonists, antiinfective agents, antihistamines and any mixtures thereof.

25. (Original) A blister form medicament pack according to claim 24, wherein said anti-inflammatory agents are selected from the group consisting of corticosteroids, NSAIDs and any mixtures thereof.

26. (Original) A blister form medicament pack according to claim 25, wherein said corticosteroids are selected from the group consisting of methyl prednisolone, prednisolone, dexamethasone, fluticasone propionate, 6 $\alpha$ ,9 $\alpha$ -difluoro-17 $\alpha$ -[(2-furanylcarbonyl)oxy]-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-androsta-1,4-

diene-17 $\beta$ -carbothioic acid S-fluoromethyl ester, 6 $\alpha$ ,9 $\alpha$ -difluoro-11 $\beta$ -hydroxy-16 $\alpha$ -methyl-3-oxo-17 $\alpha$ -propionyloxy- androsta-1,4-diene-17 $\beta$ -carbothioic acid S-(2-oxo-tetrahydro-furan-3S-yl) ester, beclomethasone esters, flunisolide, mometasone esters, triamcinolone acetonide, rofleponide, ciclesonide, butixocort propionate, RPR-106541, and ST-126 and any mixtures thereof.

27. (Original) A blister form medicament pack according to claim 25, wherein said NSAIDs are selected from the group consisting of sodium cromoglycate, nedocromil sodium, phosphodiesterase (PDE) inhibitors, leukotriene antagonists, inhibitors of leukotriene synthesis, iNOS inhibitors, tryptase and elastase inhibitors, beta-2 integrin antagonists, adenosine receptor agonists or antagonists, cytokine antagonists, inhibitors of cytokine synthesis and any mixtures thereof.

28-29. (Canceled)